세계의 칸디다질염 치료 시장 보고서(2025년)

Vulvovaginal Candidiasis Treatment Global Market Report 2025

US $ 4,490 ￦ 6,301,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,108,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,914,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

칸디다질염 치료 시장 규모는 향후 몇 년간 강력한 성장이 예상됩니다. 의료비 지출 증가, 노인 인구 증가, 만성 질환 유병률 증가, 새로운 항진균제의 개발, 질 질환에 대한 의식 증가와 관련되어 있습니다.

질 장애에 대한 인식 증가는 칸디다질염 치료 시장의 성장을 가속할 것으로 예측됩니다. 이러한 인식 증가는 향상된 교육, 더 나은 의료 접근성, 그리고 여성 건강과 웰빙에 대한 더 강력한 강조에 의해 촉진됩니다. 외음질 칸디다증의 치료는 가려움, 염증, 이상한 것 등의 증상을 완화해, 질내 세균총을 회복시켜, 감염증의 재발을 예방해, 질의 전체적인 건강과 쾌적함을 개선하는 것으로 환자를 지원합니다. 예를 들면, 2024년 10월 호주 정부 기관인 Cancer Australia는 2022년에 새롭게 진단된 질암의 사례는 123건으로 추정되어 30명이 사망했다고 보고했습니다.

칸디다질염 치료 시장의 주요 기업은 치료 효과와 환자의 편리성을 높이기 위해 경구약이나 비아졸약 등의 신규 의약품에 주력하고 있습니다. 사용하는 항진균제로, 아졸계에 속하지 않는 것을 가리키며, 진균 감염증의 대체 치료제가 됩니다. 2022년 12월 미국 기반의 생명공학 회사인 Scynexis Inc.는 재발성 외음부 칸디다증(RVVC)의 발병률을 저하시키는 경구 비아졸약인 BREXAFEMME(이브렉사판가프정)을 발표했습니다. 치료와 VVC의 재발 억제 모두의 효능과 효과로 처음으로 승인된 유일한 치료제입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 칸디다질염 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 칸디다질염 치료 시장 : 성장률 분석
• 세계의 칸디다질염 치료 시장 실적 : 규모와 성장, 2019-2024
• 세계의 칸디다질염 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계의 칸디다질염 치료 전체 시장 규모(TAM)

제6장 시장 세분화

• 세계의 칸디다질염 치료 시장 : 약제 클래스별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 클로트리마졸
• 나이스타틴
• 플루코나졸
• 케토코나졸
• 테르비나핀
• 테르코나졸
• 기타 약물 클래스
• 세계의 칸디다질염 치료 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 오랄
• 정맥내
• 주제
• 세계의 칸디다질염 치료 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 병원 약국
• 소매 약국
• 온라인 약국
• 세계의 칸디다질염 치료 시장 : 크로트리마졸유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 시판약(OTC)
• 처방약
• 세계의 칸디다질염 치료 시장 : 나이스타틴유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 단제요법
• 병용 요법
• 세계의 칸디다질염 치료 시장 : 플루코나졸유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 단회투여요법
• 다회 투여 요법
• 세계의 칸디다질염 치료 시장 : 케토코나졸유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 단기치료
• 장기치료
• 세계의 칸디다질염 치료 시장 : 테르비나핀유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 전신치료
• 국소 치료
• 세계의 칸디다질염 치료 시장 : 테르코나졸유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 저용량요법
• 고용량 요법
• 세계의 칸디다질염 치료 시장 : 기타 약물 클래스 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 아졸계 항진균제
• 폴리엔계 항진균제
• 새로운 치료법

제7장 지역별/국가별 분석

• 세계의 칸디다질염 치료 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 칸디다질염 치료 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 칸디다질염 치료 시장 :경쟁 구도
• 칸디다질염 치료 시장 : 기업 프로파일
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Dr. Reddy's Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Limited Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• Zydus Lifesciences
• Novartis Pharmaceuticals Inc.
• Glenmark Pharmaceuticals Ltd.
• Shandong Boyuan Pharmaceutical
• Taro Pharmaceuticals Industries Ltd.
• Accord Healthcare Ltd.
• Incepta Pharmaceuticals Ltd.
• Cosette Pharmaceuticals Inc.
• Crescent Pharma Ltd.
• Bhumi Pharmaceuticals
• Cidara Therapeutics Inc.
• Avet Pharmaceuticals Inc.
• Austell Pharmaceuticals Ltd.
• Laboratoire Riva Inc.
• Cadila Pharmaceuticals

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 칸디다질염 치료 시장(2029년) : 새로운 기회를 제공하는 국가
• 칸디다질염 치료 시장(2029년) : 새로운 기회를 제공하는 부문
• 칸디다질염 치료 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

SHW

영문 목차

영문목차

Vulvovaginal candidiasis treatment involves the medical management of a common fungal infection caused by Candida species, which affects the vaginal region. The goal of treatment is to ease symptoms such as itching, burning, and unusual discharge. These treatments primarily focus on reducing discomfort, restoring balance, and preventing the infection from recurring.

The primary medications used for vulvovaginal candidiasis include clotrimazole, nystatin, fluconazole, ketoconazole, terbinafine, terconazole, and others. Clotrimazole, a widely used antifungal drug, is commonly prescribed for this condition. It can be administered orally, intravenously, or topically and is available through hospital pharmacies, retail pharmacies, and online pharmacies.

The vulvovaginal candidiasis treatment market research report is one of a series of new reports from The Business Research Company that provides vulvovaginal candidiasis treatment market statistics, including vulvovaginal candidiasis treatment industry global market size, regional shares, competitors with a vulvovaginal candidiasis treatment market share, detailed vulvovaginal candidiasis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the vulvovaginal candidiasis treatment industry. This vulvovaginal candidiasis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The vulvovaginal candidiasis treatment market size has grown strongly in recent years. It will grow from $1.13 billion in 2024 to $1.19 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the rising prevalence of vulvovaginal candidiasis, the expansion of insurance coverage, the increasing number of clinical trials, advancements in research and development activities, and the growing use of broad-spectrum antibiotics.

The vulvovaginal candidiasis treatment market size is expected to see strong growth in the next few years. It will grow to $1.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period can be linked to rising healthcare expenditures, an expanding geriatric population, a higher prevalence of chronic diseases, the development of new antifungal medications, and increasing awareness of vaginal disorders. Key trends during this period include technological advancements, strategic collaborations, increased investment in research and development, innovative treatment options, and advanced therapies.

The increasing awareness of vaginal disorders is expected to drive the growth of the vulvovaginal candidiasis treatment market. Vaginal disorders encompass conditions that affect the vagina, including infections, inflammation, irritation, and abnormal discharge. This growing awareness is fueled by enhanced education, better healthcare access, and a stronger emphasis on women's health and well-being. Treatments for vulvovaginal candidiasis help patients by relieving symptoms such as itching, irritation, and abnormal discharge, restoring the vaginal microbiome, preventing recurrent infections, and improving overall vaginal health and comfort. For example, in October 2024, Cancer Australia, a government agency based in Australia, reported an estimated 123 new cases of vaginal cancer diagnosed in 2022, with 30 fatalities. As a result, the rising awareness of vaginal disorders is contributing to the expansion of the vulvovaginal candidiasis treatment market.

Leading companies in the vulvovaginal candidiasis treatment market are focusing on novel pharmaceuticals, such as oral and non-azole medications, to enhance treatment effectiveness and patient convenience. Oral and non-azole medication refers to antifungal drugs that are taken orally and do not belong to the azole class, providing an alternative treatment for fungal infections. For instance, in December 2022, Scynexis Inc., a US-based biotechnology company, introduced BREXAFEMME (ibrexafungerp tablets), an oral and non-azole medication, to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC). This medication was approved by the Food and Drug Administration (FDA), a US-based government agency, and became the first and only FDA-approved therapy for both treating vulvovaginal candidiasis (VVC) and lowering the incidence of recurrent VVC. This approval establishes BREXAFEMME as a crucial treatment option for patients with recurrent infections, offering a new approach to managing RVVC.

In February 2024, Mycovia Pharmaceuticals Inc., a US-based pharmaceutical company, partnered with Jiangsu Hengrui Pharmaceuticals Co. Ltd. to introduce VIVJOA (oteseconazole) capsules in China for the treatment of severe vulvovaginal candidiasis (VVC). Through this collaboration, Mycovia Pharmaceuticals Inc. and Jiangsu Hengrui Pharmaceuticals Co. Ltd. seek to provide an effective solution for severe vulvovaginal candidiasis, addressing patients' unmet medical needs and expanding therapeutic options for long-term fungal infection management. Jiangsu Hengrui Pharmaceuticals Co. Ltd. is a China-based company that specializes in treatments for vulvovaginal candidiasis.

Major players in the vulvovaginal candidiasis treatment market are Pfizer Inc., Bayer Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Limited, Cipla Limited, Zydus Lifesciences, Novartis Pharmaceuticals Inc., Glenmark Pharmaceuticals Ltd., Shandong Boyuan Pharmaceutical, Taro Pharmaceuticals Industries Ltd., Accord Healthcare Ltd., Incepta Pharmaceuticals Ltd., Cosette Pharmaceuticals Inc., Crescent Pharma Ltd., Bhumi Pharmaceuticals, Cidara Therapeutics Inc., Avet Pharmaceuticals Inc., Austell Pharmaceuticals Ltd., Laboratoire Riva Inc., Cadila Pharmaceuticals.

North America was the largest region in the vulvovaginal candidiasis treatment market in 2024. The regions covered in vulvovaginal candidiasis treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the vulvovaginal candidiasis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The vulvovaginal candidiasis treatment market consists of sales of antifungal creams, oral antifungal capsules, suppositories, vaginal gels, pessaries, and non-azole medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Vulvovaginal Candidiasis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on vulvovaginal candidiasis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for vulvovaginal candidiasis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vulvovaginal candidiasis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Clotrimazole; Nystatin; Fluconazole; Ketoconazole; Terbinafine; Terconazole; Other Drug Classes
• 2) By Route Of Administration: Oral; Intravenous; Topical
• 3) By Distribution Channel: Hospital Pharmacy ; Retail Pharmacy; Online Pharmacy
• Subsegments:
• 1) By Clotrimazole: Over-the-Counter (OTC) Medications; Prescription Medications
• 2) By Nystatin: Monotherapy; Combination Therapy
• 3) By Fluconazole: Single-Dose Therapy; Multi-Dose Therapy
• 4) By Ketoconazole: Short-Term Treatment; Long-Term Treatment
• 5) By Terbinafine: Systemic Treatment; Topical Treatment
• 6) By Terconazole: Low-Dose Therapy; High-Dose Therapy
• 7) By Other Drug Classes: Azole Antifungals; Polyene Antifungals; Novel Therapeutics
• Companies Mentioned: Pfizer Inc.; Bayer Inc.; Teva Pharmaceutical Industries Ltd.; Dr. Reddy's Laboratories Limited; Cipla Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Vulvovaginal Candidiasis Treatment Market Characteristics

3. Vulvovaginal Candidiasis Treatment Market Trends And Strategies

4. Vulvovaginal Candidiasis Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Vulvovaginal Candidiasis Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Vulvovaginal Candidiasis Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Vulvovaginal Candidiasis Treatment Market Growth Rate Analysis
• 5.4. Global Vulvovaginal Candidiasis Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Vulvovaginal Candidiasis Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Vulvovaginal Candidiasis Treatment Total Addressable Market (TAM)

6. Vulvovaginal Candidiasis Treatment Market Segmentation

• 6.1. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Clotrimazole
• Nystatin
• Fluconazole
• Ketoconazole
• Terbinafine
• Terconazole
• Other Drug Classes
• 6.2. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Topical
• 6.3. Global Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• 6.4. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Clotrimazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Over-the-Counter (OTC) Medications
• Prescription Medications
• 6.5. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Nystatin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monotherapy
• Combination Therapy
• 6.6. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Fluconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Dose Therapy
• Multi-Dose Therapy
• 6.7. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Ketoconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Short-Term Treatment
• Long-Term Treatment
• 6.8. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terbinafine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic Treatment
• Topical Treatment
• 6.9. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Terconazole, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Low-Dose Therapy
• High-Dose Therapy
• 6.10. Global Vulvovaginal Candidiasis Treatment Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Azole Antifungals
• Polyene Antifungals
• Novel Therapeutics

7. Vulvovaginal Candidiasis Treatment Market Regional And Country Analysis

• 7.1. Global Vulvovaginal Candidiasis Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Vulvovaginal Candidiasis Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Vulvovaginal Candidiasis Treatment Market

• 8.1. Asia-Pacific Vulvovaginal Candidiasis Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Vulvovaginal Candidiasis Treatment Market

• 9.1. China Vulvovaginal Candidiasis Treatment Market Overview
• 9.2. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Vulvovaginal Candidiasis Treatment Market

• 10.1. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Vulvovaginal Candidiasis Treatment Market

• 11.1. Japan Vulvovaginal Candidiasis Treatment Market Overview
• 11.2. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Vulvovaginal Candidiasis Treatment Market

• 12.1. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Vulvovaginal Candidiasis Treatment Market

• 13.1. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Vulvovaginal Candidiasis Treatment Market

• 14.1. South Korea Vulvovaginal Candidiasis Treatment Market Overview
• 14.2. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Vulvovaginal Candidiasis Treatment Market

• 15.1. Western Europe Vulvovaginal Candidiasis Treatment Market Overview
• 15.2. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Vulvovaginal Candidiasis Treatment Market

• 16.1. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Vulvovaginal Candidiasis Treatment Market

• 17.1. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Vulvovaginal Candidiasis Treatment Market

• 18.1. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Vulvovaginal Candidiasis Treatment Market

• 19.1. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Vulvovaginal Candidiasis Treatment Market

• 20.1. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Vulvovaginal Candidiasis Treatment Market

• 21.1. Eastern Europe Vulvovaginal Candidiasis Treatment Market Overview
• 21.2. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Vulvovaginal Candidiasis Treatment Market

• 22.1. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Vulvovaginal Candidiasis Treatment Market

• 23.1. North America Vulvovaginal Candidiasis Treatment Market Overview
• 23.2. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Vulvovaginal Candidiasis Treatment Market

• 24.1. USA Vulvovaginal Candidiasis Treatment Market Overview
• 24.2. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Vulvovaginal Candidiasis Treatment Market

• 25.1. Canada Vulvovaginal Candidiasis Treatment Market Overview
• 25.2. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Vulvovaginal Candidiasis Treatment Market

• 26.1. South America Vulvovaginal Candidiasis Treatment Market Overview
• 26.2. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Vulvovaginal Candidiasis Treatment Market

• 27.1. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Vulvovaginal Candidiasis Treatment Market

• 28.1. Middle East Vulvovaginal Candidiasis Treatment Market Overview
• 28.2. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Vulvovaginal Candidiasis Treatment Market

• 29.1. Africa Vulvovaginal Candidiasis Treatment Market Overview
• 29.2. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Vulvovaginal Candidiasis Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Vulvovaginal Candidiasis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Vulvovaginal Candidiasis Treatment Market Competitive Landscape
• 30.2. Vulvovaginal Candidiasis Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Dr. Reddy's Laboratories Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Cipla Limited Overview, Products and Services, Strategy and Financial Analysis

31. Vulvovaginal Candidiasis Treatment Market Other Major And Innovative Companies

• 31.1. Zydus Lifesciences
• 31.2. Novartis Pharmaceuticals Inc.
• 31.3. Glenmark Pharmaceuticals Ltd.
• 31.4. Shandong Boyuan Pharmaceutical
• 31.5. Taro Pharmaceuticals Industries Ltd.
• 31.6. Accord Healthcare Ltd.
• 31.7. Incepta Pharmaceuticals Ltd.
• 31.8. Cosette Pharmaceuticals Inc.
• 31.9. Crescent Pharma Ltd.
• 31.10. Bhumi Pharmaceuticals
• 31.11. Cidara Therapeutics Inc.
• 31.12. Avet Pharmaceuticals Inc.
• 31.13. Austell Pharmaceuticals Ltd.
• 31.14. Laboratoire Riva Inc.
• 31.15. Cadila Pharmaceuticals

32. Global Vulvovaginal Candidiasis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Vulvovaginal Candidiasis Treatment Market

34. Recent Developments In The Vulvovaginal Candidiasis Treatment Market

35. Vulvovaginal Candidiasis Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Vulvovaginal Candidiasis Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Vulvovaginal Candidiasis Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Vulvovaginal Candidiasis Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료